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Membrane-bound Hsp70 serves as a recognition structure
for NK cells that were pre-stimulated with Hsp70 peptide
TKD plus low dose IL-2 in vitro and in mouse models. In
a clinical phase I trial feasibility, safety and tolerability of
ex vivo TKD/IL-2 stimulated autologous NK cells has
been demonstrated in patients with metastasised colorec-
tal carcinoma and NSCLC. Based on these findings a
proof-of-concept phase II randomised clinical trial was
initiated (BMBF - Innovative therapies). NSCLC patients
will be treated with ex vivo stimulated NK cells after RCT.
Most patients are diagnosed in locally advanced disease
stages IIIA and IIIIB. After conventional radiochemother-
apy only part of the patients (less than 50%) show remis-
sion and despite improvements in standard therapies the
mortality associated with this disease is very high (5 year
survival rate does not exceed 15%). Therefore there is a
strong medical need for innovative treatment strategies.
Since an Hsp70 membrane-positive tumour phenotype is
associated with a poor clinical outcome, only Hsp70 mem-
brane-positive tumour patients are recruited into the trial.
Leukapharesis products are generated centralised and cell
processing is performed in a GMP-laboratory.
The aim of the study is to show the efficacy of the
treatment with Hsp70-peptide TKD/IL-2 activated, auto-
logous NK cells following completion of standard RCT
by improvement of PFS.
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